Phase 1B/2A Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy
Latest Information Update: 11 Sep 2026
At a glance
- Drugs CTO 1681 (Primary)
- Indications Cytokine release syndrome
- Focus Adverse reactions
- Sponsors CytoAgents
Most Recent Events
- 31 Aug 2026 Study arms increased from 3 to 5. Experimental arms CTO1681 30 µg Run-in Daily Dose / 60 µg Treatment Daily Dose and CTO1681 60 µg Run-in Daily Dose / 90 µg Treatment Daily Dose added newly. Patient population 'DLBCL' replaced with 'elapsed or refractory lymphoma or multiple myeloma.'
- 02 Dec 2025 According to a CytoAgents media release, based on these positive findings, CytoAgents is currently enrolling the second cohort of the trial, an escalated dosage of 20ug TID.
- 02 Dec 2025 According to a CytoAgents media release, company will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.